Table 2. Review of pharmacokinetic studies of sulfadoxine (continued).

Study	Volume of distribution (V)		Clearance (CL)		Absorption rate constant (ka)	Terminal half-life (t½)	Additive residual variability	Proportional residual variability	Comment
	[L]	[L/kg]	[mL/h/kg]	[L/h]	[h−1]	[h]	[µg/L]
Mansor et al. [32]	30.90a			0.084±0.013	1.30±1.10	255±61			Mean±S.D.
Obua et al. [33]		Central: 0.13±47%; peripheral: 1.6±0%		0.023±33%	0.30		2.60	27%	Estimate±CV%
Green et al. [34]	15.0 (12.1–16.0)	0.24 (0.021–0.27)	1.01 (0.82–1.61)	0.066 (0.048–0.092)		148 (121–193)			Median (IQR)
Trenque et al. [35]		2.07±0% for 11 kg		0.0108±16.3% for 11 kg	0.055	139 c	8.70	31%	Estimate±CV%
Barnes et al. [36]		0.40 (0.29–0.56)	1.85 (1.15–2.89)			161 (105–218)			Median (IQR)
Edstein et al. [34]		0.25±0.03	0.79±0.15						Mean±S.D.
Corvaisier et al. [38]		0.393±85%	2.07b		1.659±94%	132±40%			Mean±CV%
Obua et al. [39]		0.15 (0.12–0.18)	0.39 (0.30–0.56)		0.32 (0.29–0.62)	229(139–272)			Median (range)
Overall		0.25±33%	1±33%		1.5±0%	173	0	30%

^aDerived from clearance and plasma half-life (t_½).

^bDerived from clearance and elimination rate constant (λ).

^cDerived from V/CL × ln(2).

^dCorrected by a factor of (BW/11 kg)^0.72 for other body weight (BW) values.

^eCorrected by a factor of (BW/11 kg)^0..64 for other body weight (BW) values.